Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Existing data on LN in Saudi Arabia are primarily retrospective and derived from single centers. Therefore, this systematic review presents a unique and comprehensive analysis of the disease characteristics and outcomes of LN in Saudi Arabia.
Method
A systematic search of MEDLINE, ScienceDirect, Embase, Cochrane, and PubMed databases was conducted up to April 2024. Eligible articles reporting on LN in Saudi Arabia were included, and disease characteristics and outcomes were analyzed.
Results
A total of 36 studies met the inclusion criteria. The prevalence of LN among SLE patients in Saudi Arabia ranged from 19% to 55%, with biopsy-proven LN reported in 11% to 42.7% of cases. Females accounted for 66% to 94.9% of patients, with a mean age at diagnosis between 23.8 and 39.7 years. Hypertension was present in 45.8% to 62.9% of patients, with nephrotic-range proteinuria in 20.7% to 58.5% and mean serum creatinine levels between 60 and 112.68 µmol/L. Class IV LN was the most common histopathological finding, occurring in up to 72% of cases. Complete remission was achieved in up to 81.5% of patients within 12 months, though lower remission rates were observed in those with proliferative LN. End-stage renal disease (ESRD) rates ranged from 5.5% to 30.7%, with proliferative LN, older age, and hypertension being significant predictors of progression to ESRD. Five-year survival rates ranged from 92% to 96%, while 10-year survival reached 95%. Infection and renal failure were the leading causes of mortality.
Conclusion
LN is highly prevalent in lupus Saudi patients, with Class IV LN being the most common and associated with poor outcomes. Although survival has improved, many patients still progress to ESRD. Prospective trials are needed to evaluate outcomes in the current era of biological therapies.
AustinHABoumpasDTVaughanEM, et al.High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant1995; 10(9): 1620–1628.
2.
MalaviyaAChandrasekaranAKumarA, et al.Systemic lupus erythematosus in India. Lupus1997; 6(9): 690–700.
3.
JakesRWBaeSLouthrenooW, et al.Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res2012; 64(2): 159–168.
4.
CerveraRKhamashtaMAFontJ, et al.Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine1993; 72(2): 113–124.
5.
CarterEEBarrSGClarkeAE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol2016; 12(10): 605–620.
6.
TsaoBP. Genetic susceptibility to lupus nephritis. Lupus1998; 7(9): 585–590.
GolbusJMcCuneWJ. Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment. Rheum Dis Clin North Am1994; 20(1): 213–242.
9.
ArnaudLTektonidouMG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology2020; 59(Suppl5): v29–v38.
10.
Correction: survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016Ann Rheum Dis2018; 77(3): 472. DOI: 10.1136/annrheumdis-2017-211663corr1.
11.
Al ArfajAKhalilN. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus2009; 18(5): 465–473.
12.
QariFA. Clinical pattern of systemic lupus erythematosus in Western Saudi Arabia. Saudi Med J2002; 23(10): 1247–1250.
13.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev2021; 10(1): 89.
14.
HigginsJPTAltmanDGGøtzschePC, et al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928.
15.
National Heart, Lung and BI. Study Quality Assessment Tools.
16.
AlbirdisiMRAl-HomoodIA. Characteristics of lupus nephritis in Saudi lupus patients: a retrospective observational study. Lupus2020; 29(12): 1638–1643.
17.
Al ArfajASKhalilNAl SalehS. Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. Rheumatol Int2009; 29(9): 1057–1067.
18.
BawazirY. Clinicopathological correlation of patients with lupus nephritis: data from a tertiary center in Saudi Arabia. Medicine2024; 103(14): e37821.
19.
MirghaniHOAbdul Khalig AlyoussefAMohammedOS. The relationship between dyslipidemia and lupus nephritis in systemic lupus erythematosus patients attending a Saudi Rheumatic Center, Tabuk. Sudan J Med Sci2020; 15: 10–19. DOI: 10.18502/sjms.v15i1.6697, Published online.
20.
HasanMAAlaliLAlsadahF, et al.Prevalence and patterns of renal involvement among patients with systemic lupus erythematous at a tertiary center. J Clin Rheumatol2023; 29(2): 84–90.
21.
MitwalliAHAl WakeelJSAl MohayaSS, et al.Pattern of glomerular disease in Saudi Arabia. Am J Kidney Dis1996; 27(6): 797–802.
22.
Al-HomranyMAlghamdiSAl-HwieshA, et al.Pattern of renal diseases and the need for establishment of renal biopsy registry in Saudi Arabia. Saudi J Kidney Dis Transpl2019; 30(3): 628–633.
23.
AlMathamKIAlFayezAFAlHarthiRA, et al.Glomerulonephritis disease pattern at Saudi tertiary care center. Saudi Med J2017; 38(11): 1113–1117.
24.
BerniehBSirwalIAAbbadiMA, et al.The spectrum of glomerulonephritis in adults in madinah munawarah region. Saudi J Kidney Dis Transpl2000; 11(3): 455–460.
25.
AlFaadhelTAlsuwaidaAAlsaadK, et al.Prevalence and 20-year epidemiological trends of glomerular diseases in the adult Saudi population: a multicenter study. Ann Saudi Med2019; 39(3): 155–161.
26.
ShawarbyMAl TamimiDAlMS, et al.A clinicopathologic study of glomerular disease: experience of the King Fahd Hospital of the University, Eastern Province, Saudi Arabia. Hong Kong J Nephrol2010; 12(1): 20–30.
27.
MitwalliAHAl WakeelJAbu-AishaH, et al.Prevalence of glomerular diseases: king Khalid university hospital, Saudi Arabia. Saudi J Kidney Dis Transpl2000; 11(3): 442–448.
28.
AslamNKhawajaNNawazZ, et al.Pattern of glomerular disease in the Saudi population: a single-center, five-year retrospective study. Saudi J Kidney Dis Transplant2013; 24(6): 1265–1270.
29.
HuraibSAl KhaderAShaheenFA, et al.The spectrum of glomerulonephritis in Saudi Arabia: the results of the Saudi registry. Saudi J Kidney Dis Transpl2000; 11(3): 434–441.
30.
JalalahSM. Changing frequency of glomerular diseases in Western Saudi Arabia: a 26-year experience. J Microsc Ultrastruct2020; 8(3): 89–95.
31.
AlkhunaiziAM. Pattern of renal pathology among renal biopsy specimens in Eastern Saudi Arabia. Saudi Med J2007; 28(11): 1676–1681.
32.
GomaaWBahlasSHabhabW, et al.Clinicopathological characteristics of lupus nephritis in Western region of Saudi Arabia: an experience from two tertiary medical centres. J Microsc Ultrastruct2014; 2(1): 12–19.
33.
AlsuwaidaAHusainSAl GhonaimM, et al.Prognostic significance of C1q deposition in serial biopsies for predicating the long-term outcome in patients with proliferative lupus nephritis. Saudi J Kidney Dis Transpl2016; 27(2): 305–311.
34.
AlmalkiAHAlrowaieFAAlhozaliHM, et al.Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia. Lupus2019; 28(9): 1082–1090.
35.
AlsuwaidaA. Interstitial inflammation and long-term renal outcomes in lupus nephritis. Lupus2013; 22(14): 1446–1454.
36.
AlsuwaidaAHusainSAl GhonaimM, et al.Glomerular necrotic lesions and long-term outcomes among patients with proliferative lupus nephritis. Int J Clin Exp Pathol2015; 8(5): 5787–5792.
37.
AlsuwaidaAOBakhitAAAlsuwaidaFA, et al.The long-term outcomes and histological transformation in class II lupus nephritis. Saudi Med J2018; 39(10): 990–993.
38.
AlaiyaAAssadLAlkhafajiD, et al.Proteomic analysis of Class IV lupus nephritis. Nephrol Dial Transplant2015; 30(1): 62–70.
39.
AlsuwaidaAHusainSAlghonaimM, et al.Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant2012; 27(4): 1472–1478.
40.
DurahimHAl GhamdiGAl SerayaA, et al.Predictors of mortality and end stage renal disease in Saudi patients with lupus nephritis. Lupus2011; 20(12): 1329–1335.
41.
OudahNAl DuhailibZAlsaadK, et al.Glomerulonephritis with crescents among adult Saudi patients outcome and its predictors. Clin Exp Med2012; 12(2): 121–125.
42.
KfouryH. Tubulo-reticular inclusions in lupus nephritis: are they relevant?Saudi J Kidney Dis Transpl2014; 25(3): 539–543.
43.
MitwalliAHAl WakeelJSHurraibS, et al.Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial. Saudi J Kidney Dis Transpl2011; 22(5): 935–940.
44.
MitwalliAHHayatAAlwakeelJ, et al.Effects of concomitant hepatitis C virus infection in patients with underlying lupus nephritis on long-term renal outcome. Nephrol Dial Transplant2012; 27(2): 627–632.
45.
BastianHMRosemanJMMcgwinG, et al.Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus2002; 11(3): 152–160.
46.
FeldmanCHHirakiLTLiuJ, et al.Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum2013; 65(3): 753–763.
47.
HanlyJGO’KeeffeAGSuL, et al.The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology2016; 55(2): 252–262.
48.
AdamichouCNikolopoulosDGenitsaridiI, et al.In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis2020; 79(2): 232–241.
49.
ParodisILanataCNikolopoulosD, et al.Reframing health disparities in SLE: a critical reassessment of racial and ethnic differences in lupus disease outcomes. Best Pract Res Clin Rheumatol2023; 37(4): 101894.
50.
GheitaTANoorRAAbualfadlE, et al.Adult systemic lupus erythematosus in Egypt: the nation-wide spectrum of 3661 patients and world-wide standpoint. Lupus2021; 30(9): 1526–1535.
51.
KhanfirMSHoumanMHCherifE, et al.TULUP (TUnisian LUPus): a multicentric study of systemic lupus erythematosus in Tunisia. Int J Rheum Dis2013; 16(5): 539–546.
52.
NeumannKWallaceDJAzenC, et al.Lupus in the 1980s: III. Influence of clinical variables, biopsy,and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum1995; 25(1): 47–55.
53.
BrugosBKissESzodorayP, et al.Retrospective analysis of patients with lupus nephritis: data from a large clinical immunological center in Hungary. Scand J Immunol2006; 64(4): 433–437.
54.
PakozdiARajakariarRPyneD, et al.Systematic review and the external validity of randomized controlled trials in lupus nephritis. Kidney Int Rep2018; 3(2): 403–411.
55.
WangHRenY-LChangJ, et al.A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol2018; 33(1): 17–25.
56.
WashioMKiyoharaCOhtaA. Epidemiology of systemic lupus erythematosus. Lupus - New Advances and Challenges. London: IntechOpen, 2020. DOI: 10.5772/intechopen.84146.
57.
HirakiLTFeldmanCHLiuJ, et al.Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. Arthritis Rheum2012; 64(8): 2669–2676.
58.
AbbasiMSRSultanKNaeemullahN, et al.The prevalence of different classes of lupus nephritis based on ISN/RPN 2003 classification system keeping renal biopsy as standard for diagnosis. J Popul Ther Clin Pharmacol2023; 30(17): 1644–1651. DOI: 10.53555/jptcp.v30i17.2733, Published online September.
59.
FanouriakisAKostopoulouMCheemaK, et al.2019 update of the Joint European League against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis2020; 79(6): 713–723.
60.
HahnBHMcMahonMAWilkinsonA, et al.American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res2012; 64(6): 797–808.
61.
RovinBHAyoubIMChanTM, et al.KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int2024; 105(1S): S1–S69.
62.
MoroniGVercelloniPGQuagliniS, et al.Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis2018; 77(9): 1318–1325.
63.
MakACheakAACTanJYS, et al.Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology2009; 48(8): 944–952.
64.
ZhuBChenNLinY, et al.Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant2007; 22(7): 1933–1942.
65.
MomtazMFayedAWadieM, et al.Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. Lupus2017; 26(14): 1564–1570.
66.
KorbetSMSchwartzMMEvansJ, et al.Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol2007; 18(1): 244–254.
67.
MoroniGQuagliniSGallelliB, et al.The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant2007; 22(9): 2531–2539.
68.
ContrerasGLenzOPardoV, et al.Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int2006; 69(10): 1846–1851.
69.
TektonidouMGDasguptaAWardMM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol2016; 68(6): 1432–1441.
70.
YapDYHTangCSOMaMKM, et al.Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant2012; 27(8): 3248–3254.
71.
IppolitoAPetriM. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol2008; 26(5 Suppl 51): S72–S79.
72.
FaurschouMDreyerLKamperA, et al.Long-term mortality and renal outcome in a cohort of 100 patients with Lupus Nephritis. Arthritis Care Res2010; 62(6): 873–880.
73.
TehCLPhuiVELingGR, et al.Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience. Clin Kidney J2018; 11(1): 56–61.
74.
BonoLCameronJSHicksJA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM1999; 92(4): 211–218.
75.
Reppe MoeSEMolbergØStrømEH, et al.Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort. Lupus2019; 28(7): 818–825.
76.
AmehOIKengneAPJayneD, et al.Standard of treatment and outcomes of adults with lupus nephritis in Africa: a systematic review. Lupus2016; 25(11): 1269–1277.
77.
IchinoseKKitamuraMSatoS, et al.Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort. Arthritis Res Ther2020; 22(1): 175.
78.
LuoWFarinhaFIsenbergDA, et al.Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up. Rheumatology2022; 62(1): 200–208.
79.
ZenMSalmasoLBarbiellini AmideiC, et al.Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study. Eur J Intern Med2023; 112: 45–51.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
